Get all premium features to the best stock analysis tool

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

MAINZ, Germany, March 24, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data from its diversified portfolio in the field of lung cancer at the European Lung Cancer Congress (“ELCC”) held in Copenhagen, Denmark, from March 25-28, 2026. The data updates covered in both oral and poster presentations highlight progress across late-stage immunomodulator candidates pumitamig and gotistobart, as well as antibody-drug conjugate (“ADC”) programs, across various lung cancer subtypes and lines of treatment. BioNTech's clinical portfolio encompasses both monotherapies and combinations with standard of care treatments, as well as novel-novel combination regimens aimed at delivering differentiated therapeutic profiles for the treatment of patients with lung cancer across all stages of the disease.

BioNTech SE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of BioNTech SE (NASDAQ: BNTX). The investigation focuses on BioNTech's executive officers and whether investor losses may be recovered under federal securities laws.

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L11/VEGF-A bispecific immunomodulator pumitamig with e ight global Phase 3 clinical trials planned to be ongoing for year-end in collaboration with Bristol Myers Squibb Full year 2025 revenues of €2.9 billion 2 , net loss of €1.1 billion (adjusted3 net loss of €0.1 billion) and diluted loss per share of €4.70 ($5.31 4 ) (adjusted3 diluted loss per share of €0.48 ($0.55 4 )) Strong financial position continues to de-risk execution with cash, cash equivalents and security investments of €17.2 billion5 Expect 2026 total revenues of €2.0 billion to €2.3 billion, adjusted3 R&D expenses between €2.2-2.5 billion and adjusted3 SG&A expenses7 between €700-800 million BioNTech co-founders Ugur Sahin and Özlem Türeci to establish an independent company  with a focus on next-generation mRNA innovations; management transition by end of 2026 Conference call and webcast scheduled for March 10, 2026, at 8:00 a.m. EDT (1:00 p.m.

BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030

Mainz, Germany, March 10, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced plans for an independent company to be established and led by BioNTech co-founders Prof. Ugur Sahin, M.D., and Prof. Özlem Türeci, M.D. The new company with distinct resources, operations and funding options, will advance next-generation mRNA innovations. BioNTech plans to contribute related rights and mRNA technologies to the new company to enable and support the prioritized development of next-generation mRNA innovations with disruptive potential. With both companies focusing on their respective strategic priorities, BioNTech expects to maximize value for patients and shareholders alike.